A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease-Reference-Cited by-同舟云学术

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

Published:2019-06 Issue:6 Volume:126 Page:792-800
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Wirta David L.,Torkildsen Gail L.,Moreira Helen R.^ORCID,Lonsdale John D.^ORCID,Ciolino Joseph B.,Jentsch Garrit,Beckert Michael,Ousler George W.^ORCID,Steven Philipp,Krösser Sonja

Publisher

Elsevier BV

Subject

Ophthalmology

Reference28 articles.

1. Utility assessment among patients with dry eye disease;Schiffman;Ophthalmology,2003

2. Cyclosporine A delivery to the eye: a pharmaceutical challenge;Lallemand;Eur J Pharm Biopharm,2003

3. CsA Phase 3 study group, two randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease;Sall;Ophthalmology,2000

4. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomized, vehicle controlled phase III clinical studies;Leonardi;Br J Ophthalmol,2018

5. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery;Dutescu;E J Pham Biopharm,2014

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Qingxuan Runmu Yin alleviates dry eye disease via inhibition of the HMOX1/HIF-1 pathway affecting ferroptosis;Frontiers in Pharmacology;2024-09-11

2. Rosmarinic acid-grafted gelatin nanogels for efficient diquafosol delivery in dry eye disease therapy;Journal of Controlled Release;2024-09

3. The evolution of cyclosporine treatments for treatment of ocular surface diseases;Current Opinion in Allergy & Clinical Immunology;2024-07-24

4. Membrane Fusion‐Mediated Loading of Therapeutic siRNA into Exosome for Tissue‐Specific Application;Advanced Materials;2024-07

5. Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE;Cornea;2024-05-21